U.S. Markets closed

Advaxis reports survival and new analysis for ADXS-HPV in cervical cancer

Advaxis announced final 12 month overall survival and additional data from Lm-LLO-E7-15, a randomized Phase 2 study evaluating the safety and efficacy of ADXS-HPV +/- cisplatin in patients with recurrent cervical cancer. The data were presented by Dr. Robert Petit, Chief Scientific Officer at Advaxis, at the 2013 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL, on Sunday, June 2. As of May 17, the trial has completed enrollment and 110 patients have received 264 doses of ADXS-HPV. Final 12 month overall survival is 36% (39/110) with a current 18 month survival of 22% (16/73). This compares to 33% and 17%, respectively, at the last update and are the best results yet reported for this study. “These data suggest that ADXS-HPV has the potential to become a non-chemotherapy treatment option capable of improving survival for women with cervical cancer. Clinical benefit was evident in this trial even in women with cancer that recurred aggressively, who had bulky metastatic tumors, and who had been previously treated with both chemotherapy and radiotherapy. The side effects reported by less than half of the patients were mild, and associated primarily with the infusion. Furthermore, the ability of ADXS-HPV in this study to cause durable complete and partial remission of solid tumors as a monotherapy, is very promising,” commented Dr. Robert Petit, Chief Scientific Officer at Advaxis.